agalsidase beta (GZ419828)

DRUG3 trials

Sponsors

Sanofi

Conditions

Fabry DiseaseFabry's Disease

Phase 3

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

Active, not recruitingNCT05280548

SanofiFabry Disease

Start: 2022-05-03End: 2027-12-06Updated: 2026-03-10

Phase 4

To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease

WithdrawnNCT04143958

SanofiFabry Disease

Start: 2020-09-30End: 2023-11-30Updated: 2023-04-07

A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

CompletedNCT06019728

SanofiFabry's Disease

Start: 2023-11-10End: 2024-10-25Updated: 2025-10-21

Related Papers

#197 A phase 4 study to evaluate the safety and tolerability of higher infusion rates of agalsidase beta to shorten the infusion duration in Fabry disease—Preliminary data

Nephrology Dialysis Transplantation2025-10-01